5-aminosalicylic acid in the treatment of ulcerative colitis and Crohn's disease;Ulcerøs kolitt, Crohns sykdom og 5-aminosalisylsyreforbindelser

Tidsskrift for den Norske Laegeforening

Volumn 123, Issue 18, 2003, Pages 2565-2567

  Moum, Bjørn ^a  

^a Sykehuset Østfold Fredrikstad   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BALSALAZIDE; COLAZID; MESALAZINE; OLSALAZINE; PLACEBO; SALAZOSULFAPYRIDINE; NONSTEROID ANTIINFLAMMATORY AGENT;

COLORECTAL CANCER; CROHN DISEASE; DISEASE EXACERBATION; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG EFFICACY; DRUG SAFETY; HUMAN; REMISSION; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; ULCERATIVE COLITIS; RECURRENT DISEASE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; MESALAMINE; RECURRENCE;

EID: 1342289470     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Logan RFA. Inflammatory bowel disease incidence: up, down or unchanged? Gut 1998; 42: 309-11.
2. Nikolaus S, Folsch UR, Schreiber S. Immunopharmacology of 5-aminosalicylic acid and of glucocorticoids in the therapy of inflammatory bowel disease. Hepatogastroenterology 2000; 47: 71-82.
3. Greenfield SM, Punchard NA, Tear JP, Thompson RP. The mode of action of the aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther 1993; 7: 369-83.
4. Riely SA. What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis? Gut 1998; 42: 761-3.
5. Svartz N. Salazopyrin, a new sulfianilamide preparation. A. Theraputic results in rheumatic poly-arthritis. B. Therapeutic results in ulcerative colitis. C. Toxic manifestations in treatment with sulfanilamide preparations. Acta Med Scand 1942; 110: 557-90.
6. Klotz U. The role of aminosalicylates at the beginning of the new millenium in the treatment of chronic inflammatory bowel disease. Eur J Clin Pharmacol 2000; 56: 353-62.
7. Gisbert JP, Gomollon F, Mate J, Pajares JM. Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease. A systematic review. Dig Dis Sci 2002; 47: 471-88.
8. Kruis W, Schreiber S, Theuer D, Brandes J-W, Schutz E, Howaldt S et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3. 0 g twice daily) was superior in preventing relapses. Gut 2000; 49: 783-9.
9. Green JBR, Lobo AJ, Holdsworth CD, Leicester RJ, Gibson JA, Kerr GD et al. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. Gastroenterology 1998; 114: 15-22.
10. Marshall JK, Irvine EJ. Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis. Aliment Pharmacol Ther 1995; 9: 293-300.
11. Safdi M, deMicco M, Sninsky C, Banks P, Wruble L, Deren J et al. A double-blind comparison of oral versus rectal mesalazine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997; 92: 1867-71.
12. Sutherland LR. Aminosalicylates in the treatment of ulcerative colitis and Crohn's disease. I: Rutgeerts P, Colombel J-F, Hanauer SB, Schölmerich J, Tytgat GNJ, van Gossum A, red. Advances in inflammatory bowel diseases. Dordrecht: Kluwer, 1999: 201-9.
13. Marteau P, Crand J, Foucault M, Rambaud J-C. Use of mesalazine slow release suppositories 1g three times per week to maintain remission of ulcerative proctitis: a randomised double-blind placebo controlled multicentre study. Gut 1998; 42: 195-9.
14. Prakash A, Markham A. Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease. Drugs 1999; 57: 383-408.
15. Singelton J. Second trial of mesalamine therapy in the treatment of active Crohn's disease. Gastroenterology 1994; 107: 632-3.
16. Thomsen O, Cortot A, Jewell D, Wright JP, Winter T, Veloso FT et al. A comparison of budesonide and mesalamine for active Crohn's disease. N Engl J Med 1998; 339: 370-4.
17. Lochs H. Mayer M, Fleig WE, Mortensen PB, Bauer P et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine. Gastroenterology 2000; 118: 264-73.
18. Camma C, Giunta M, Rosselli M, Cottone M. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis ajusted for confounding variables. Gastroenterology 1997; 113: 1465-73.
19. Sutherland LR. Mesalamine for the prevention of postoperative recurrence: is nearly there the same as being there? Gastroenterology 2000; 118: 346-8.
20. Cottone M, Camma C, Sutherland LR. Mesalamine and relapse prevention in Crohns disease. Gastroenterology 2000; 116: 597.
21. Rutgeerts P. Infliximab for ulcerative colitis: the need for adequately powered placebo-controlled trials. Am J Gastroenterol 2002; 10: 2488-9.
22. Sutherland LR, Roth DE, Beck PL. Alternatives to sulfasalazine: a meta-analysis of 5-ASA in the treatment of ulcerative colitis. Inflamm Bowel Dis 1997; 3: 65-78.
23. Ekbom A, Kornfeld A. Sulphasalazine use as a preventive factor for colorectal cancer in ulcerative colitis patients - a review. Inflamm Bowel Dis 1996; 2: 276-8.
24. Allgayer H, Kruis W. Aminosalicylates: potential antineoplastic actions in colon cancer prevention. Scand J Gastroenterol 2002; 38: 125-31.
25. Eaden J, Abrams K, Ekbom A, Jackson E, Mayberry J. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharamacol Ther 2000; 14:145-53.
26. Bernstein CN, Eaden J, Steinhart AH, Munkholm P, Gordon P. Cancer prevention in inflammatory bowel diseases and the chemoprophylatic potential of 5-aminosalicylic acid. Inflamm Bowel Dis 2002; 8: 356-61.